CompletedNCT01323205
Safety and Tolerability of JNJ-40411813 for Schizophrenia
About this title
Read the official source — NCT01323205Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Innsbruck and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium, Austria, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01323205
- Official title
Show the full official title
First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Innsbruck, Austria · Salzburg, Austria · Vienna, Austria
17 more locations
- Dave, Belgium
- Duffel, Belgium
- Kortenberg, Belgium
- Lede, Belgium
- Plovdiv, Bulgaria
- Radnevo, Bulgaria
- Berlin, Germany
- Hamburg, Germany
- Mainz, Germany
- Mannheim, Germany
- München, Germany
- Arad, Romania
- Brasov, Romania
- Iași, Romania
- Sibiu, Romania
- Barcelona, Spain
- Zamora, Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-40411813, Placebo and Antipsychotic medication.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication